South Korea Gene Therapy Market Size & Outlook, 2023-2030
Related Markets
South Korea gene therapy market highlights
- The South Korea gene therapy market generated a revenue of USD 6.5 million in 2023 and is expected to reach USD 9.6 million by 2030.
- The South Korea market is expected to grow at a CAGR of 5.7% from 2024 to 2030.
- In terms of segment, lentivirus was the largest revenue generating vector type in 2023.
- Lentivirus is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 6.5 million |
| Market revenue in 2030 | USD 9.6 million |
| Growth rate | 5.7% (CAGR from 2024 to 2030) |
| Largest segment | Lentivirus |
| Fastest growing segment | Lentivirus |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lentivirus, AAV |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, South Korea accounted for 0.1% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 246.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Gensight Biologics SA | View profile | 46 | 74, rue du Faubourg Saint-Antoine, Paris, France, 75012 | https://www.gensight-biologics.com |
| Ultragenyx Pharmaceutical Inc | View profile | 1276 | 60 Leveroni Court, Novato, CA, United States, 94949 | https://www.ultragenyx.com |
| Regenxbio Inc | View profile | 344 | 9804 Medical Center Drive, Rockville, MD, United States, 20850 | https://www.regenxbio.com |
| Oxford Biomedical Research | View profile | 11-50 | Rochester Hills, Michigan, United States, North America | https://www.oxfordbiomed.com/ |
| Benitec Biopharma Inc | View profile | 16 | 3940 Trust Way, Hayward, CA, United States, 94545 | https://www.benitec.com |
| Transgene SA | View profile | 158 | 400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, France, 67400 | https://www.transgene.fr |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | https://www.sangamo.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | https://www.bluebirdbio.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | https://www.cellectis.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | https://www.sibiono.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | https://www.uniqure.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
South Korea gene therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gene therapy market will help companies and investors design strategic landscapes.
Lentivirus was the largest segment with a revenue share of 50.77% in 2023. Horizon Databook has segmented the South Korea gene therapy market based on lentivirus, aav covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is the 12th largest market in the healthcare industry. The South Korean government has planned to invest more than USD 1.7 billion in the country's biotechnology and biopharmaceutical sector.
The country is one of the key markets for regenerative medicine as it was the first to commercialize stem cell therapy. The Korean government is also supportive of the adoption of gene therapy products.
For instance, in 2019, the government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals, which allows conditional approval for the commercial sale of phase II completed drugs.
Reasons to subscribe to South Korea gene therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea gene therapy market databook
-
Our clientele includes a mix of gene therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea gene therapy market , including forecasts for subscribers. This country databook contains high-level insights into South Korea gene therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea gene therapy market size, by indication, 2018-2030 (US$M)
South Korea Gene Therapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
